Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-260-7120
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees88
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions
What is Iovance Biotherapeutics' stock symbol?
Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."
How were Iovance Biotherapeutics' earnings last quarter?
Iovance Biotherapeutics Inc (NASDAQ:IOVA) posted its earnings results on Thursday, August, 1st. The biotechnology company reported ($0.38) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $0.09. View Iovance Biotherapeutics' Earnings History.
When is Iovance Biotherapeutics' next earnings date?
What price target have analysts set for IOVA?
11 brokers have issued 12 month price objectives for Iovance Biotherapeutics' stock. Their predictions range from $27.00 to $34.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $30.80 in the next twelve months. This suggests a possible upside of 57.4% from the stock's current price. View Analyst Price Targets for Iovance Biotherapeutics.
What is the consensus analysts' recommendation for Iovance Biotherapeutics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iovance Biotherapeutics.
What are Wall Street analysts saying about Iovance Biotherapeutics stock?
Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (10/17/2019)
- 2. HC Wainwright analysts commented, "Our thesis on TILs stands strong. In accordance with our thesis, showing efficacy in solid tumors beyond melanoma continues to represent a game changer for Iovance and, on a broader look, we continue to view this company as a viable takeout candidate for Big Pharma. We would like to reiterate that, apart from academic-based TILs therapies such as NCI and MD Anderson, Iovance is the only biotech that is developing a commercial TIL product to treat a variety of tumors and patients using the predefined cryopreserved 22-day manufacturing strategy." (7/2/2019)
- 3. Chardan Capital analysts commented, "We therefore expect to see a similar rate in the registration-directed Cohort 4 which is currently enrolling." (5/31/2019)
Has Iovance Biotherapeutics been receiving favorable news coverage?
Headlines about IOVA stock have been trending somewhat negative on Saturday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iovance Biotherapeutics earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Iovance Biotherapeutics.
Are investors shorting Iovance Biotherapeutics?
Iovance Biotherapeutics saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 14,260,000 shares, an increase of 6.9% from the August 30th total of 13,340,000 shares. Based on an average trading volume of 1,340,000 shares, the short-interest ratio is currently 10.6 days. Currently, 12.8% of the company's shares are sold short. View Iovance Biotherapeutics' Current Options Chain.
Who are some of Iovance Biotherapeutics' key competitors?
Some companies that are related to Iovance Biotherapeutics include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), bluebird bio (BLUE), Moderna (MRNA), China Biologic Products (CBPO), argenx (ARGX), Repligen (RGEN), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN) and Crispr Therapeutics (CRSP).
What other stocks do shareholders of Iovance Biotherapeutics own?
Who are Iovance Biotherapeutics' key executives?
Iovance Biotherapeutics' management team includes the folowing people:
- Dr. Maria Fardis, CEO, Pres & Director (Age 51)
- Mr. Timothy E. Morris, CFO, Principal Accounting Officer, Corp. Sec. & Treasurer (Age 57)
- Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 45)
- Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 59)
- Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 62)
Who are Iovance Biotherapeutics' major shareholders?
Iovance Biotherapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.52%), Rhenman & Partners Asset Management AB (0.42%), Bailard Inc. (0.14%), Coastal Investment Advisors Inc. (0.02%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Institutional Ownership Trends for Iovance Biotherapeutics.
Which major investors are selling Iovance Biotherapeutics stock?
Which major investors are buying Iovance Biotherapeutics stock?
IOVA stock was bought by a variety of institutional investors in the last quarter, including Bailard Inc., Meeder Asset Management Inc. and Coastal Investment Advisors Inc.. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Insider Buying and Selling for Iovance Biotherapeutics.
How do I buy shares of Iovance Biotherapeutics?
Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Iovance Biotherapeutics' stock price today?
One share of IOVA stock can currently be purchased for approximately $19.57.
How big of a company is Iovance Biotherapeutics?
Iovance Biotherapeutics has a market capitalization of $2.42 billion. The biotechnology company earns $-123,580,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.View Additional Information About Iovance Biotherapeutics.
What is Iovance Biotherapeutics' official website?
How can I contact Iovance Biotherapeutics?
Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]
MarketBeat Community Rating for Iovance Biotherapeutics (NASDAQ IOVA)
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
